DEVELOPMENT OF NOVEL THERAPIES FOR NIDDM

NIDDM 新型疗法的开发

• 批准号: 7357880
• 负责人: CHRISTOPHER B NEWGARD
• 金额: $ 1.17万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-01 至 2007-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7357880
• 关键词: Adenoviridae; balance; birth; family; genes; glucose; glycogen; glycogen synthase; model; phosphoprotein phosphatase; protein structure; proteins

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Recombinant adenoviruses are a tool for delivery of genes that can modulate the balance between hepatic glucose disposal and production in animal models of diabetes, thereby gaining insights into mechanisms of hepatic dysfunction in the disease as well as novel therapeutic strategies. In recent years this work has focused on a family of glycogen targeting subunits of protein phosphatase-1 (PP-1). The proteins serve as scaffolds for juxtaposing PP-1 with its substrates glycogen phosphorylase, glycogen synthase, and phosphorylase kinase. Early collaborative studies with the Rogers Center used 13C NMR to demonstrate that adenovirus-mediated expression of PTG, a targeting subunit family member, stimulates glycogen synthesis by the indirect (gluconeogenic) pathway.

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。重组腺病毒是一种基因传递工具，可以在糖尿病动物模型中调节肝脏葡萄糖处理和产生之间的平衡，从而深入了解糖尿病肝功能障碍的机制以及新的治疗策略。近年来，这项工作主要集中在针对蛋白磷酸酶-1亚单位(PP-1)的糖原家族。这些蛋白质作为支架将PP-1与其底物糖原磷酸化酶、糖原合成酶和磷酸化酶激酶并列。早期与罗杰斯中心的合作研究使用13C核磁共振证明，腺病毒介导的PTG的表达，一个靶向亚单位家族成员，通过间接(糖异生)途径刺激糖原合成。